Immunochina to ramp up cell therapy development after finance round

Beijing-based biotech Immunochina Pharmaceuticals reportedly raised RMB 100 million via Series C+ financing round, funneled by Zhongguancun Longmen Investment. Proceeds will go towards research and development (R&D) of the firm's novel cancer therapy pipeline, and to prepare for commercialization. Previously, Immunochina raised RMB 150 million (around USD 22 million) via a Series C financing round held in January 2019.

Founded in 2015, Immunochina applies cutting-edge gene cell therapy technologies to treat malignant tumors. Notably, its chimeric antigen receptor (CAR) T cell product IM19 won an ethical approval from the Beijing Cancer Hospital (BCH) for assessment in recurrent/refractory (r/r) non-Hodgkin’s lymphoma (nHL) in July this year. In addition, the company is developing several CAR-T cell therapies targeting hematological and solid tumors, with investigational new drug (IND) filings expected next year.


Related news
JW Therapeutics, the cell therapy joint venture (JV) between Juno and WuXi AppTec, has passed the hearing to list on the Hong Kong Stock Exchange (HKSE).
US-based CASI Pharmaceuticals Inc., (Nasdaq.CAS) announced it is restructuring a partnership with Beijing-based Juventas Cell Therapy Ltd relating to CNCT19, an investigational CD19 chimeric antigen receptor (CAR) T Cell therapy.
China's Center for Drug Evaluation (CDE) website indicates that JW Therapeutics, a joint venture between US-based cell therapy specialist Juno Therapeutics and Chinese Contract Research Organization (CRO) WuXi AppTec Group, received priority review status for its chimeric antigen receptor (CAR)-T cell product candidate JWCAR029.
Fosun Kite Biotechnology Co., Ltd, a joint venture between US-based Kite Pharma and China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (600196.SH), entered a strategic partnership agreement with Cytiva, previously known as GE Healthcare Life Sciences.
JW Therapeutics, the cell therapy joint venture (JV) between Juno and WuXi AppTec, filed to list on the Hong Kong Stock Exchange this week.
Recent news
Mexican authorities last week revealed that the SARS-CoV-2 vaccine advanced purchases that were announced recently will include 51 million doses from the World Health Organization (WHO)’s COVAX initiative, up to 34 million of Pfizer’s double-dose immunization, 77 million of AstraZeneca (AZ)’s double-dose vaccine, and 35 million of CanSino’s single-dose treatment, totalling 197 million doses for 116.7 million people.
According to GBI analysis, Chile's Institute of Public Health (ISP) this week published the approvals of US firm Pfizer’s biosimilar Ruxience (rituximab), Netherlands-based Synthon’s Gatrel (sunitinib), a first-in-market generic version of Pfizer’s Sutent, as well as Argentina-based Varifarma’s Nibclus (ponatinib), a first-mover generic of Pint Pharma’s Iclusig.
Brazil’s Ministry of Science, Technology, Innovation and Communication (MCTIC) this week announced results of a clinical trial (CT) evaluating the efficacy of broad-range antiviral nitazoxanide against early-stage COVID-19.
Óscar Vicente Scavone, president of Paraguay-based Laboratorios Éticos, last week commented on the local pharmaceutical industry’s situation and prospects amid the COVID-19 pandemic.
Russian bank and financial services giant Sberbank and compatriot pharma firm JSC Pharmasyntez signed a cooperation agreement on October 14, 2020.
The National Healthcare Security Administration (NHSA) released a notification in relation to the diagnosis-related group (DRG)-style payment pilot work plan, including plans to roll out an “index/points” system that will enable DRG.
China food delivery giant Meituan struck up a strategic partnership with Germany-based giant Bayer’s Consumer Health Division in China.
Analytics Snapshot

Analytics Snapshot